nodes	percent_of_prediction	percent_of_DWPC	metapath
Lenalidomide—PTGS2—melanoma	0.261	0.54	CbGaD
Lenalidomide—ABCB1—melanoma	0.222	0.46	CbGaD
Lenalidomide—TNFSF11—leg—melanoma	0.0245	0.207	CbGeAlD
Lenalidomide—TNFSF11—hindlimb—melanoma	0.0219	0.185	CbGeAlD
Lenalidomide—TNFSF11—appendage—melanoma	0.0188	0.159	CbGeAlD
Lenalidomide—CDH5—endothelium—melanoma	0.00854	0.072	CbGeAlD
Lenalidomide—CDH5—blood vessel—melanoma	0.00788	0.0664	CbGeAlD
Lenalidomide—CDH5—mammalian vulva—melanoma	0.00333	0.0281	CbGeAlD
Lenalidomide—Thalidomide—NFKB1—melanoma	0.00328	0.426	CrCbGaD
Lenalidomide—PTGS2—leg—melanoma	0.00319	0.0269	CbGeAlD
Lenalidomide—TNFSF11—head—melanoma	0.00316	0.0267	CbGeAlD
Lenalidomide—PTGS2—hindlimb—melanoma	0.00285	0.0241	CbGeAlD
Lenalidomide—CRBN—retina—melanoma	0.00264	0.0223	CbGeAlD
Lenalidomide—PTGS2—appendage—melanoma	0.00245	0.0206	CbGeAlD
Lenalidomide—CDH5—head—melanoma	0.00238	0.0201	CbGeAlD
Lenalidomide—TNFSF11—lymph node—melanoma	0.00221	0.0187	CbGeAlD
Lenalidomide—CRBN—mammalian vulva—melanoma	0.00211	0.0178	CbGeAlD
Lenalidomide—PTGS2—skin epidermis—melanoma	0.00204	0.0172	CbGeAlD
Lenalidomide—CDH5—lymph node—melanoma	0.00167	0.0141	CbGeAlD
Lenalidomide—Pomalidomide—TNF—melanoma	0.00156	0.203	CrCbGaD
Lenalidomide—CRBN—head—melanoma	0.00151	0.0128	CbGeAlD
Lenalidomide—PTGS2—endothelium—melanoma	0.00148	0.0125	CbGeAlD
Lenalidomide—PTGS2—blood vessel—melanoma	0.00136	0.0115	CbGeAlD
Lenalidomide—CRBN—lymph node—melanoma	0.00106	0.00893	CbGeAlD
Lenalidomide—Thalidomide—TNF—melanoma	0.001	0.131	CrCbGaD
Lenalidomide—ABCB1—blood vessel—melanoma	0.000843	0.00711	CbGeAlD
Lenalidomide—Pomalidomide—PTGS2—melanoma	0.00074	0.0963	CrCbGaD
Lenalidomide—PTGS2—skin of body—melanoma	0.000631	0.00532	CbGeAlD
Lenalidomide—Pomalidomide—ABCB1—melanoma	0.00063	0.0819	CrCbGaD
Lenalidomide—Thalidomide—PTGS2—melanoma	0.000477	0.0621	CrCbGaD
Lenalidomide—ABCB1—retina—melanoma	0.000444	0.00375	CbGeAlD
Lenalidomide—PTGS2—head—melanoma	0.000412	0.00347	CbGeAlD
Lenalidomide—ABCB1—mammalian vulva—melanoma	0.000356	0.003	CbGeAlD
Lenalidomide—PTGS2—lymph node—melanoma	0.000288	0.00243	CbGeAlD
Lenalidomide—ABCB1—head—melanoma	0.000255	0.00215	CbGeAlD
Lenalidomide—Liver function test abnormal—Docetaxel—melanoma	0.000201	0.000934	CcSEcCtD
Lenalidomide—Vomiting—Vemurafenib—melanoma	0.0002	0.00093	CcSEcCtD
Lenalidomide—Alopecia—Temozolomide—melanoma	0.0002	0.00093	CcSEcCtD
Lenalidomide—Dry skin—Docetaxel—melanoma	0.000199	0.000927	CcSEcCtD
Lenalidomide—Chest pain—Bleomycin—melanoma	0.000199	0.000924	CcSEcCtD
Lenalidomide—Myalgia—Bleomycin—melanoma	0.000199	0.000924	CcSEcCtD
Lenalidomide—Abdominal pain upper—Docetaxel—melanoma	0.000199	0.000924	CcSEcCtD
Lenalidomide—Rash—Vemurafenib—melanoma	0.000198	0.000922	CcSEcCtD
Lenalidomide—Mental disorder—Temozolomide—melanoma	0.000198	0.000922	CcSEcCtD
Lenalidomide—Dermatitis—Vemurafenib—melanoma	0.000198	0.000921	CcSEcCtD
Lenalidomide—Back pain—Carmustine—melanoma	0.000197	0.000917	CcSEcCtD
Lenalidomide—Headache—Vemurafenib—melanoma	0.000197	0.000916	CcSEcCtD
Lenalidomide—Malnutrition—Temozolomide—melanoma	0.000197	0.000916	CcSEcCtD
Lenalidomide—Erythema—Temozolomide—melanoma	0.000197	0.000916	CcSEcCtD
Lenalidomide—Breast disorder—Docetaxel—melanoma	0.000197	0.000914	CcSEcCtD
Lenalidomide—Discomfort—Bleomycin—melanoma	0.000196	0.000913	CcSEcCtD
Lenalidomide—Malaise—Dactinomycin—melanoma	0.000196	0.000913	CcSEcCtD
Lenalidomide—Cramp muscle—Docetaxel—melanoma	0.000196	0.000911	CcSEcCtD
Lenalidomide—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000196	0.000911	CcSEcCtD
Lenalidomide—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000196	0.000911	CcSEcCtD
Lenalidomide—Leukopenia—Dactinomycin—melanoma	0.000195	0.000906	CcSEcCtD
Lenalidomide—Nasopharyngitis—Docetaxel—melanoma	0.000194	0.000904	CcSEcCtD
Lenalidomide—Dysgeusia—Temozolomide—melanoma	0.000193	0.000897	CcSEcCtD
Lenalidomide—Confusional state—Bleomycin—melanoma	0.000192	0.000894	CcSEcCtD
Lenalidomide—Vision blurred—Carmustine—melanoma	0.000192	0.000893	CcSEcCtD
Lenalidomide—Alanine aminotransferase increased—Docetaxel—melanoma	0.000192	0.000892	CcSEcCtD
Lenalidomide—Tremor—Carmustine—melanoma	0.000191	0.000888	CcSEcCtD
Lenalidomide—Oedema—Bleomycin—melanoma	0.000191	0.000886	CcSEcCtD
Lenalidomide—Back pain—Temozolomide—melanoma	0.00019	0.000886	CcSEcCtD
Lenalidomide—Infection—Bleomycin—melanoma	0.000189	0.00088	CcSEcCtD
Lenalidomide—Anaemia—Carmustine—melanoma	0.000188	0.000876	CcSEcCtD
Lenalidomide—Dysphagia—Docetaxel—melanoma	0.000188	0.000874	CcSEcCtD
Lenalidomide—Agitation—Carmustine—melanoma	0.000187	0.000871	CcSEcCtD
Lenalidomide—Nausea—Vemurafenib—melanoma	0.000187	0.000869	CcSEcCtD
Lenalidomide—Thrombocytopenia—Bleomycin—melanoma	0.000187	0.000868	CcSEcCtD
Lenalidomide—Vision blurred—Temozolomide—melanoma	0.000186	0.000863	CcSEcCtD
Lenalidomide—Myalgia—Dactinomycin—melanoma	0.000185	0.000862	CcSEcCtD
Lenalidomide—Tremor—Temozolomide—melanoma	0.000185	0.000858	CcSEcCtD
Lenalidomide—Discomfort—Dactinomycin—melanoma	0.000183	0.000852	CcSEcCtD
Lenalidomide—Angina pectoris—Docetaxel—melanoma	0.000183	0.000852	CcSEcCtD
Lenalidomide—Ill-defined disorder—Temozolomide—melanoma	0.000183	0.00085	CcSEcCtD
Lenalidomide—Leukopenia—Carmustine—melanoma	0.000182	0.000848	CcSEcCtD
Lenalidomide—Anaemia—Temozolomide—melanoma	0.000182	0.000847	CcSEcCtD
Lenalidomide—Anorexia—Bleomycin—melanoma	0.000182	0.000845	CcSEcCtD
Lenalidomide—Agitation—Temozolomide—melanoma	0.000181	0.000842	CcSEcCtD
Lenalidomide—Angioedema—Temozolomide—melanoma	0.00018	0.000837	CcSEcCtD
Lenalidomide—Pancytopenia—Docetaxel—melanoma	0.000178	0.00083	CcSEcCtD
Lenalidomide—ABCB1—lymph node—melanoma	0.000178	0.0015	CbGeAlD
Lenalidomide—Hypotension—Bleomycin—melanoma	0.000178	0.000828	CcSEcCtD
Lenalidomide—Oedema—Dactinomycin—melanoma	0.000178	0.000826	CcSEcCtD
Lenalidomide—Malaise—Temozolomide—melanoma	0.000178	0.000826	CcSEcCtD
Lenalidomide—Vertigo—Temozolomide—melanoma	0.000177	0.000823	CcSEcCtD
Lenalidomide—Infection—Dactinomycin—melanoma	0.000177	0.000821	CcSEcCtD
Lenalidomide—Leukopenia—Temozolomide—melanoma	0.000176	0.00082	CcSEcCtD
Lenalidomide—Hypertension—Carmustine—melanoma	0.000176	0.000818	CcSEcCtD
Lenalidomide—Neutropenia—Docetaxel—melanoma	0.000176	0.000817	CcSEcCtD
Lenalidomide—Palpitations—Temozolomide—melanoma	0.000174	0.000809	CcSEcCtD
Lenalidomide—Thrombocytopenia—Dactinomycin—melanoma	0.000174	0.000809	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Bleomycin—melanoma	0.000174	0.000807	CcSEcCtD
Lenalidomide—Myalgia—Carmustine—melanoma	0.000173	0.000807	CcSEcCtD
Lenalidomide—Chest pain—Carmustine—melanoma	0.000173	0.000807	CcSEcCtD
Lenalidomide—Anxiety—Carmustine—melanoma	0.000173	0.000804	CcSEcCtD
Lenalidomide—Cough—Temozolomide—melanoma	0.000172	0.000799	CcSEcCtD
Lenalidomide—Paraesthesia—Bleomycin—melanoma	0.000171	0.000796	CcSEcCtD
Lenalidomide—Weight increased—Docetaxel—melanoma	0.000171	0.000796	CcSEcCtD
Lenalidomide—Weight decreased—Docetaxel—melanoma	0.00017	0.000791	CcSEcCtD
Lenalidomide—Hypertension—Temozolomide—melanoma	0.00017	0.000791	CcSEcCtD
Lenalidomide—Dyspnoea—Bleomycin—melanoma	0.00017	0.00079	CcSEcCtD
Lenalidomide—Anorexia—Dactinomycin—melanoma	0.000169	0.000788	CcSEcCtD
Lenalidomide—Pneumonia—Docetaxel—melanoma	0.000169	0.000784	CcSEcCtD
Lenalidomide—Confusional state—Carmustine—melanoma	0.000168	0.00078	CcSEcCtD
Lenalidomide—Arthralgia—Temozolomide—melanoma	0.000168	0.00078	CcSEcCtD
Lenalidomide—Myalgia—Temozolomide—melanoma	0.000168	0.00078	CcSEcCtD
Lenalidomide—Infestation NOS—Docetaxel—melanoma	0.000168	0.000779	CcSEcCtD
Lenalidomide—Infestation—Docetaxel—melanoma	0.000168	0.000779	CcSEcCtD
Lenalidomide—Anxiety—Temozolomide—melanoma	0.000167	0.000777	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000167	0.000774	CcSEcCtD
Lenalidomide—Oedema—Carmustine—melanoma	0.000166	0.000774	CcSEcCtD
Lenalidomide—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000166	0.000773	CcSEcCtD
Lenalidomide—Discomfort—Temozolomide—melanoma	0.000166	0.00077	CcSEcCtD
Lenalidomide—Decreased appetite—Bleomycin—melanoma	0.000166	0.00077	CcSEcCtD
Lenalidomide—Infection—Carmustine—melanoma	0.000165	0.000768	CcSEcCtD
Lenalidomide—Acute coronary syndrome—Docetaxel—melanoma	0.000165	0.000768	CcSEcCtD
Lenalidomide—Renal failure—Docetaxel—melanoma	0.000165	0.000766	CcSEcCtD
Lenalidomide—Myocardial infarction—Docetaxel—melanoma	0.000164	0.000764	CcSEcCtD
Lenalidomide—Neuropathy peripheral—Docetaxel—melanoma	0.000164	0.000764	CcSEcCtD
Lenalidomide—Dry mouth—Temozolomide—melanoma	0.000164	0.000763	CcSEcCtD
Lenalidomide—Stomatitis—Docetaxel—melanoma	0.000163	0.00076	CcSEcCtD
Lenalidomide—Pain—Bleomycin—melanoma	0.000163	0.000758	CcSEcCtD
Lenalidomide—Conjunctivitis—Docetaxel—melanoma	0.000163	0.000758	CcSEcCtD
Lenalidomide—Thrombocytopenia—Carmustine—melanoma	0.000163	0.000757	CcSEcCtD
Lenalidomide—Tachycardia—Carmustine—melanoma	0.000162	0.000755	CcSEcCtD
Lenalidomide—Confusional state—Temozolomide—melanoma	0.000162	0.000754	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000162	0.000753	CcSEcCtD
Lenalidomide—Oedema—Temozolomide—melanoma	0.000161	0.000748	CcSEcCtD
Lenalidomide—Infection—Temozolomide—melanoma	0.00016	0.000743	CcSEcCtD
Lenalidomide—Anorexia—Carmustine—melanoma	0.000159	0.000737	CcSEcCtD
Lenalidomide—Hepatobiliary disease—Docetaxel—melanoma	0.000158	0.000737	CcSEcCtD
Lenalidomide—Epistaxis—Docetaxel—melanoma	0.000158	0.000735	CcSEcCtD
Lenalidomide—Nervous system disorder—Temozolomide—melanoma	0.000158	0.000733	CcSEcCtD
Lenalidomide—Thrombocytopenia—Temozolomide—melanoma	0.000157	0.000732	CcSEcCtD
Lenalidomide—Feeling abnormal—Bleomycin—melanoma	0.000157	0.00073	CcSEcCtD
Lenalidomide—Agranulocytosis—Docetaxel—melanoma	0.000156	0.000727	CcSEcCtD
Lenalidomide—Skin disorder—Temozolomide—melanoma	0.000156	0.000726	CcSEcCtD
Lenalidomide—Hypotension—Carmustine—melanoma	0.000155	0.000723	CcSEcCtD
Lenalidomide—Hyperhidrosis—Temozolomide—melanoma	0.000155	0.000723	CcSEcCtD
Lenalidomide—Decreased appetite—Dactinomycin—melanoma	0.000154	0.000718	CcSEcCtD
Lenalidomide—Fatigue—Dactinomycin—melanoma	0.000153	0.000713	CcSEcCtD
Lenalidomide—Anorexia—Temozolomide—melanoma	0.000153	0.000713	CcSEcCtD
Lenalidomide—Pain—Dactinomycin—melanoma	0.000152	0.000707	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Carmustine—melanoma	0.000152	0.000705	CcSEcCtD
Lenalidomide—Urticaria—Bleomycin—melanoma	0.000151	0.000704	CcSEcCtD
Lenalidomide—Haemoglobin—Docetaxel—melanoma	0.000151	0.000703	CcSEcCtD
Lenalidomide—Rhinitis—Docetaxel—melanoma	0.000151	0.000701	CcSEcCtD
Lenalidomide—Body temperature increased—Bleomycin—melanoma	0.000151	0.000701	CcSEcCtD
Lenalidomide—Haemorrhage—Docetaxel—melanoma	0.00015	0.0007	CcSEcCtD
Lenalidomide—Hepatitis—Docetaxel—melanoma	0.00015	0.0007	CcSEcCtD
Lenalidomide—Insomnia—Carmustine—melanoma	0.00015	0.0007	CcSEcCtD
Lenalidomide—Hypoaesthesia—Docetaxel—melanoma	0.00015	0.000696	CcSEcCtD
Lenalidomide—Paraesthesia—Carmustine—melanoma	0.000149	0.000695	CcSEcCtD
Lenalidomide—Pharyngitis—Docetaxel—melanoma	0.000149	0.000694	CcSEcCtD
Lenalidomide—Urinary tract disorder—Docetaxel—melanoma	0.000149	0.000691	CcSEcCtD
Lenalidomide—Dyspnoea—Carmustine—melanoma	0.000148	0.00069	CcSEcCtD
Lenalidomide—Oedema peripheral—Docetaxel—melanoma	0.000148	0.000689	CcSEcCtD
Lenalidomide—Somnolence—Carmustine—melanoma	0.000148	0.000688	CcSEcCtD
Lenalidomide—Connective tissue disorder—Docetaxel—melanoma	0.000148	0.000688	CcSEcCtD
Lenalidomide—Urethral disorder—Docetaxel—melanoma	0.000147	0.000686	CcSEcCtD
Lenalidomide—Feeling abnormal—Dactinomycin—melanoma	0.000146	0.000681	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Temozolomide—melanoma	0.000146	0.000681	CcSEcCtD
Lenalidomide—Insomnia—Temozolomide—melanoma	0.000145	0.000676	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Dactinomycin—melanoma	0.000145	0.000676	CcSEcCtD
Lenalidomide—Visual impairment—Docetaxel—melanoma	0.000145	0.000674	CcSEcCtD
Lenalidomide—Decreased appetite—Carmustine—melanoma	0.000145	0.000672	CcSEcCtD
Lenalidomide—Paraesthesia—Temozolomide—melanoma	0.000144	0.000671	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Carmustine—melanoma	0.000144	0.000668	CcSEcCtD
Lenalidomide—Dyspnoea—Temozolomide—melanoma	0.000143	0.000666	CcSEcCtD
Lenalidomide—Somnolence—Temozolomide—melanoma	0.000143	0.000665	CcSEcCtD
Lenalidomide—Erythema multiforme—Docetaxel—melanoma	0.000142	0.000662	CcSEcCtD
Lenalidomide—Pain—Carmustine—melanoma	0.000142	0.000661	CcSEcCtD
Lenalidomide—Constipation—Carmustine—melanoma	0.000142	0.000661	CcSEcCtD
Lenalidomide—Dyspepsia—Temozolomide—melanoma	0.000141	0.000658	CcSEcCtD
Lenalidomide—Eye disorder—Docetaxel—melanoma	0.000141	0.000654	CcSEcCtD
Lenalidomide—Abdominal pain—Dactinomycin—melanoma	0.00014	0.000653	CcSEcCtD
Lenalidomide—Body temperature increased—Dactinomycin—melanoma	0.00014	0.000653	CcSEcCtD
Lenalidomide—Hypersensitivity—Bleomycin—melanoma	0.00014	0.000653	CcSEcCtD
Lenalidomide—Decreased appetite—Temozolomide—melanoma	0.00014	0.00065	CcSEcCtD
Lenalidomide—Flushing—Docetaxel—melanoma	0.00014	0.000649	CcSEcCtD
Lenalidomide—Cardiac disorder—Docetaxel—melanoma	0.00014	0.000649	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Temozolomide—melanoma	0.000139	0.000645	CcSEcCtD
Lenalidomide—Fatigue—Temozolomide—melanoma	0.000139	0.000644	CcSEcCtD
Lenalidomide—Constipation—Temozolomide—melanoma	0.000137	0.000639	CcSEcCtD
Lenalidomide—Pain—Temozolomide—melanoma	0.000137	0.000639	CcSEcCtD
Lenalidomide—Feeling abnormal—Carmustine—melanoma	0.000137	0.000637	CcSEcCtD
Lenalidomide—Asthenia—Bleomycin—melanoma	0.000137	0.000636	CcSEcCtD
Lenalidomide—Angiopathy—Docetaxel—melanoma	0.000136	0.000635	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Carmustine—melanoma	0.000136	0.000633	CcSEcCtD
Lenalidomide—Immune system disorder—Docetaxel—melanoma	0.000136	0.000632	CcSEcCtD
Lenalidomide—Mediastinal disorder—Docetaxel—melanoma	0.000136	0.000631	CcSEcCtD
Lenalidomide—Chills—Docetaxel—melanoma	0.000135	0.000628	CcSEcCtD
Lenalidomide—Pruritus—Bleomycin—melanoma	0.000135	0.000627	CcSEcCtD
Lenalidomide—Arrhythmia—Docetaxel—melanoma	0.000134	0.000625	CcSEcCtD
Lenalidomide—Alopecia—Docetaxel—melanoma	0.000133	0.000618	CcSEcCtD
Lenalidomide—Feeling abnormal—Temozolomide—melanoma	0.000132	0.000616	CcSEcCtD
Lenalidomide—Mental disorder—Docetaxel—melanoma	0.000132	0.000613	CcSEcCtD
Lenalidomide—Body temperature increased—Carmustine—melanoma	0.000131	0.000611	CcSEcCtD
Lenalidomide—Abdominal pain—Carmustine—melanoma	0.000131	0.000611	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Temozolomide—melanoma	0.000131	0.000611	CcSEcCtD
Lenalidomide—Erythema—Docetaxel—melanoma	0.000131	0.000609	CcSEcCtD
Lenalidomide—Malnutrition—Docetaxel—melanoma	0.000131	0.000609	CcSEcCtD
Lenalidomide—Hypersensitivity—Dactinomycin—melanoma	0.000131	0.000609	CcSEcCtD
Lenalidomide—Dysgeusia—Docetaxel—melanoma	0.000128	0.000596	CcSEcCtD
Lenalidomide—Urticaria—Temozolomide—melanoma	0.000128	0.000594	CcSEcCtD
Lenalidomide—Asthenia—Dactinomycin—melanoma	0.000127	0.000593	CcSEcCtD
Lenalidomide—Abdominal pain—Temozolomide—melanoma	0.000127	0.000591	CcSEcCtD
Lenalidomide—Body temperature increased—Temozolomide—melanoma	0.000127	0.000591	CcSEcCtD
Lenalidomide—Back pain—Docetaxel—melanoma	0.000127	0.000589	CcSEcCtD
Lenalidomide—Muscle spasms—Docetaxel—melanoma	0.000126	0.000586	CcSEcCtD
Lenalidomide—Hypersensitivity—Carmustine—melanoma	0.000123	0.00057	CcSEcCtD
Lenalidomide—Diarrhoea—Dactinomycin—melanoma	0.000122	0.000565	CcSEcCtD
Lenalidomide—Vomiting—Bleomycin—melanoma	0.000121	0.000563	CcSEcCtD
Lenalidomide—Anaemia—Docetaxel—melanoma	0.000121	0.000563	CcSEcCtD
Lenalidomide—Rash—Bleomycin—melanoma	0.00012	0.000559	CcSEcCtD
Lenalidomide—Dermatitis—Bleomycin—melanoma	0.00012	0.000558	CcSEcCtD
Lenalidomide—Asthenia—Carmustine—melanoma	0.000119	0.000555	CcSEcCtD
Lenalidomide—Hypersensitivity—Temozolomide—melanoma	0.000118	0.000551	CcSEcCtD
Lenalidomide—Syncope—Docetaxel—melanoma	0.000117	0.000546	CcSEcCtD
Lenalidomide—Leukopenia—Docetaxel—melanoma	0.000117	0.000545	CcSEcCtD
Lenalidomide—Palpitations—Docetaxel—melanoma	0.000116	0.000538	CcSEcCtD
Lenalidomide—Asthenia—Temozolomide—melanoma	0.000115	0.000536	CcSEcCtD
Lenalidomide—Loss of consciousness—Docetaxel—melanoma	0.000115	0.000535	CcSEcCtD
Lenalidomide—Cough—Docetaxel—melanoma	0.000114	0.000532	CcSEcCtD
Lenalidomide—Diarrhoea—Carmustine—melanoma	0.000114	0.000529	CcSEcCtD
Lenalidomide—Pruritus—Temozolomide—melanoma	0.000114	0.000529	CcSEcCtD
Lenalidomide—Nausea—Bleomycin—melanoma	0.000113	0.000526	CcSEcCtD
Lenalidomide—Hypertension—Docetaxel—melanoma	0.000113	0.000526	CcSEcCtD
Lenalidomide—Vomiting—Dactinomycin—melanoma	0.000113	0.000525	CcSEcCtD
Lenalidomide—Rash—Dactinomycin—melanoma	0.000112	0.000521	CcSEcCtD
Lenalidomide—Arthralgia—Docetaxel—melanoma	0.000111	0.000519	CcSEcCtD
Lenalidomide—Chest pain—Docetaxel—melanoma	0.000111	0.000519	CcSEcCtD
Lenalidomide—Myalgia—Docetaxel—melanoma	0.000111	0.000519	CcSEcCtD
Lenalidomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000111	0.000515	CcSEcCtD
Lenalidomide—Dizziness—Carmustine—melanoma	0.00011	0.000512	CcSEcCtD
Lenalidomide—Diarrhoea—Temozolomide—melanoma	0.00011	0.000511	CcSEcCtD
Lenalidomide—Dry mouth—Docetaxel—melanoma	0.000109	0.000507	CcSEcCtD
Lenalidomide—Confusional state—Docetaxel—melanoma	0.000108	0.000501	CcSEcCtD
Lenalidomide—Oedema—Docetaxel—melanoma	0.000107	0.000497	CcSEcCtD
Lenalidomide—Dizziness—Temozolomide—melanoma	0.000106	0.000494	CcSEcCtD
Lenalidomide—Infection—Docetaxel—melanoma	0.000106	0.000494	CcSEcCtD
Lenalidomide—Vomiting—Carmustine—melanoma	0.000106	0.000492	CcSEcCtD
Lenalidomide—Nausea—Dactinomycin—melanoma	0.000106	0.000491	CcSEcCtD
Lenalidomide—Shock—Docetaxel—melanoma	0.000105	0.000489	CcSEcCtD
Lenalidomide—Rash—Carmustine—melanoma	0.000105	0.000488	CcSEcCtD
Lenalidomide—Nervous system disorder—Docetaxel—melanoma	0.000105	0.000488	CcSEcCtD
Lenalidomide—Dermatitis—Carmustine—melanoma	0.000105	0.000487	CcSEcCtD
Lenalidomide—Thrombocytopenia—Docetaxel—melanoma	0.000105	0.000487	CcSEcCtD
Lenalidomide—Tachycardia—Docetaxel—melanoma	0.000104	0.000485	CcSEcCtD
Lenalidomide—Headache—Carmustine—melanoma	0.000104	0.000485	CcSEcCtD
Lenalidomide—Skin disorder—Docetaxel—melanoma	0.000104	0.000483	CcSEcCtD
Lenalidomide—Vomiting—Temozolomide—melanoma	0.000102	0.000475	CcSEcCtD
Lenalidomide—Anorexia—Docetaxel—melanoma	0.000102	0.000474	CcSEcCtD
Lenalidomide—Rash—Temozolomide—melanoma	0.000101	0.000471	CcSEcCtD
Lenalidomide—Dermatitis—Temozolomide—melanoma	0.000101	0.000471	CcSEcCtD
Lenalidomide—Headache—Temozolomide—melanoma	0.000101	0.000468	CcSEcCtD
Lenalidomide—Hypotension—Docetaxel—melanoma	9.99e-05	0.000465	CcSEcCtD
Lenalidomide—Nausea—Carmustine—melanoma	9.88e-05	0.000459	CcSEcCtD
Lenalidomide—Musculoskeletal discomfort—Docetaxel—melanoma	9.74e-05	0.000453	CcSEcCtD
Lenalidomide—Insomnia—Docetaxel—melanoma	9.67e-05	0.00045	CcSEcCtD
Lenalidomide—Paraesthesia—Docetaxel—melanoma	9.6e-05	0.000446	CcSEcCtD
Lenalidomide—Nausea—Temozolomide—melanoma	9.55e-05	0.000444	CcSEcCtD
Lenalidomide—Dyspnoea—Docetaxel—melanoma	9.53e-05	0.000443	CcSEcCtD
Lenalidomide—Somnolence—Docetaxel—melanoma	9.5e-05	0.000442	CcSEcCtD
Lenalidomide—Dyspepsia—Docetaxel—melanoma	9.41e-05	0.000438	CcSEcCtD
Lenalidomide—Decreased appetite—Docetaxel—melanoma	9.29e-05	0.000432	CcSEcCtD
Lenalidomide—Gastrointestinal disorder—Docetaxel—melanoma	9.23e-05	0.000429	CcSEcCtD
Lenalidomide—Fatigue—Docetaxel—melanoma	9.21e-05	0.000429	CcSEcCtD
Lenalidomide—Constipation—Docetaxel—melanoma	9.14e-05	0.000425	CcSEcCtD
Lenalidomide—Pain—Docetaxel—melanoma	9.14e-05	0.000425	CcSEcCtD
Lenalidomide—Feeling abnormal—Docetaxel—melanoma	8.81e-05	0.00041	CcSEcCtD
Lenalidomide—Gastrointestinal pain—Docetaxel—melanoma	8.74e-05	0.000407	CcSEcCtD
Lenalidomide—Abdominal pain—Docetaxel—melanoma	8.45e-05	0.000393	CcSEcCtD
Lenalidomide—Body temperature increased—Docetaxel—melanoma	8.45e-05	0.000393	CcSEcCtD
Lenalidomide—Hypersensitivity—Docetaxel—melanoma	7.87e-05	0.000366	CcSEcCtD
Lenalidomide—Asthenia—Docetaxel—melanoma	7.67e-05	0.000357	CcSEcCtD
Lenalidomide—Pruritus—Docetaxel—melanoma	7.56e-05	0.000352	CcSEcCtD
Lenalidomide—Diarrhoea—Docetaxel—melanoma	7.31e-05	0.00034	CcSEcCtD
Lenalidomide—Dizziness—Docetaxel—melanoma	7.07e-05	0.000329	CcSEcCtD
Lenalidomide—Vomiting—Docetaxel—melanoma	6.8e-05	0.000316	CcSEcCtD
Lenalidomide—Rash—Docetaxel—melanoma	6.74e-05	0.000313	CcSEcCtD
Lenalidomide—Dermatitis—Docetaxel—melanoma	6.73e-05	0.000313	CcSEcCtD
Lenalidomide—Headache—Docetaxel—melanoma	6.7e-05	0.000311	CcSEcCtD
Lenalidomide—Nausea—Docetaxel—melanoma	6.35e-05	0.000295	CcSEcCtD
Lenalidomide—ABCB1—Allograft Rejection—IL2—melanoma	4.08e-05	0.000233	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—CCND1—melanoma	4.07e-05	0.000232	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—melanoma	4.06e-05	0.000232	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—APC—melanoma	4.03e-05	0.00023	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—melanoma	4e-05	0.000228	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGF—melanoma	3.99e-05	0.000228	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—KRAS—melanoma	3.95e-05	0.000226	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MMP9—melanoma	3.95e-05	0.000226	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—FGF2—melanoma	3.91e-05	0.000223	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—TNF—melanoma	3.84e-05	0.000219	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGF1—melanoma	3.81e-05	0.000217	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	3.76e-05	0.000215	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—E2F1—melanoma	3.72e-05	0.000213	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	3.69e-05	0.000211	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—melanoma	3.69e-05	0.000211	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MDM2—melanoma	3.66e-05	0.000209	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PRKCA—melanoma	3.65e-05	0.000208	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—ERBB2—melanoma	3.61e-05	0.000206	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—melanoma	3.58e-05	0.000204	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	3.57e-05	0.000204	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CUL3—melanoma	3.56e-05	0.000204	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TRRAP—melanoma	3.56e-05	0.000204	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CB—melanoma	3.56e-05	0.000203	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—melanoma	3.51e-05	0.000201	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ACER3—melanoma	3.49e-05	0.000199	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKR1B10—melanoma	3.46e-05	0.000198	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—VEGFA—melanoma	3.46e-05	0.000198	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—melanoma	3.45e-05	0.000197	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CXCL8—melanoma	3.42e-05	0.000196	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	3.39e-05	0.000194	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—melanoma	3.38e-05	0.000193	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	3.37e-05	0.000193	CbGpPWpGaD
Lenalidomide—PTGS2—C-MYB transcription factor network—HRAS—melanoma	3.36e-05	0.000192	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK3—melanoma	3.35e-05	0.000192	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1B—melanoma	3.34e-05	0.000191	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CASP3—melanoma	3.28e-05	0.000187	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL2—melanoma	3.27e-05	0.000187	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MYC—melanoma	3.26e-05	0.000186	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	3.22e-05	0.000184	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—melanoma	3.21e-05	0.000184	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—UGT2B10—melanoma	3.19e-05	0.000182	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—MAPK1—melanoma	3.19e-05	0.000182	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—EGFR—melanoma	3.19e-05	0.000182	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CCND1—melanoma	3.19e-05	0.000182	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	3.18e-05	0.000181	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLCB4—melanoma	3.17e-05	0.000181	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CTNNB1—melanoma	3.16e-05	0.00018	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	3.13e-05	0.000179	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—FASN—melanoma	3.11e-05	0.000178	CbGpPWpGaD
Lenalidomide—PTGS2—Selenium Micronutrient Network—IL6—melanoma	3.1e-05	0.000177	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MMP9—melanoma	3.1e-05	0.000177	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—LUM—melanoma	3.09e-05	0.000176	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—CDKN1A—melanoma	3.08e-05	0.000176	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PTEN—melanoma	3.08e-05	0.000176	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NFKB1—melanoma	3.06e-05	0.000175	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—melanoma	3.05e-05	0.000174	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TNF—melanoma	3.04e-05	0.000174	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—melanoma	3.04e-05	0.000173	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HPSE—melanoma	3.03e-05	0.000173	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC6A11—melanoma	2.98e-05	0.00017	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIP4K2A—melanoma	2.98e-05	0.00017	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CUBN—melanoma	2.97e-05	0.00017	CbGpPWpGaD
Lenalidomide—ABCB1—Allograft Rejection—TNF—melanoma	2.97e-05	0.00017	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HS3ST5—melanoma	2.97e-05	0.00017	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—MTAP—melanoma	2.9e-05	0.000166	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	2.9e-05	0.000166	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CSPG4—melanoma	2.87e-05	0.000164	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—melanoma	2.86e-05	0.000163	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	2.84e-05	0.000162	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	2.84e-05	0.000162	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—melanoma	2.83e-05	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RPS3—melanoma	2.82e-05	0.000161	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—SKI—melanoma	2.78e-05	0.000159	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—VEGFA—melanoma	2.78e-05	0.000159	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	2.77e-05	0.000158	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—STAT3—melanoma	2.75e-05	0.000157	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—NRAS—melanoma	2.75e-05	0.000157	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	2.74e-05	0.000156	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—TP53—melanoma	2.68e-05	0.000153	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	2.68e-05	0.000153	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	2.67e-05	0.000153	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	2.66e-05	0.000152	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	2.66e-05	0.000152	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK3—melanoma	2.63e-05	0.00015	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	2.62e-05	0.00015	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—LUM—melanoma	2.59e-05	0.000148	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PHGDH—melanoma	2.59e-05	0.000148	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MYC—melanoma	2.56e-05	0.000146	CbGpPWpGaD
Lenalidomide—ABCB1—HIF-1-alpha transcription factor network—AKT1—melanoma	2.55e-05	0.000146	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—HPSE—melanoma	2.54e-05	0.000145	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	2.53e-05	0.000144	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—MAPK1—melanoma	2.5e-05	0.000143	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—EGFR—melanoma	2.5e-05	0.000143	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CUBN—melanoma	2.49e-05	0.000142	CbGpPWpGaD
Lenalidomide—PTGS2—Spinal Cord Injury—IL6—melanoma	2.45e-05	0.00014	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	2.41e-05	0.000138	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	2.41e-05	0.000137	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SDHD—melanoma	2.4e-05	0.000137	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—BSG—melanoma	2.4e-05	0.000137	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CSPG4—melanoma	2.4e-05	0.000137	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—KRAS—melanoma	2.36e-05	0.000135	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GPAM—melanoma	2.33e-05	0.000133	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HDAC6—melanoma	2.3e-05	0.000131	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	2.28e-05	0.000131	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	2.28e-05	0.00013	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	2.25e-05	0.000129	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLCB4—melanoma	2.25e-05	0.000128	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	2.22e-05	0.000127	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—melanoma	2.22e-05	0.000127	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NPPA—melanoma	2.18e-05	0.000124	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—PIK3CA—melanoma	2.17e-05	0.000124	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	2.17e-05	0.000124	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	2.17e-05	0.000124	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	2.17e-05	0.000124	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—VCAN—melanoma	2.12e-05	0.000121	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC6A11—melanoma	2.11e-05	0.000121	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIP4K2A—melanoma	2.11e-05	0.000121	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—WNT5A—melanoma	2.11e-05	0.00012	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—TP53—melanoma	2.1e-05	0.00012	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—melanoma	2.07e-05	0.000118	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—SLC5A5—melanoma	2.06e-05	0.000118	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—MTAP—melanoma	2.06e-05	0.000118	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	2.06e-05	0.000117	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	2.05e-05	0.000117	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	2.01e-05	0.000115	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—HRAS—melanoma	2.01e-05	0.000115	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PLA2G6—melanoma	1.98e-05	0.000113	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	1.96e-05	0.000112	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	1.94e-05	0.000111	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—IL6—melanoma	1.92e-05	0.00011	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	1.9e-05	0.000108	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	1.89e-05	0.000108	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	1.88e-05	0.000108	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	1.88e-05	0.000108	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—LUM—melanoma	1.83e-05	0.000105	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PHGDH—melanoma	1.83e-05	0.000105	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—melanoma	1.82e-05	0.000104	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—HPSE—melanoma	1.8e-05	0.000103	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—VCAN—melanoma	1.78e-05	0.000102	CbGpPWpGaD
Lenalidomide—CDH5—Signaling Pathways—AKT1—melanoma	1.77e-05	0.000101	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CUBN—melanoma	1.76e-05	0.000101	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	1.71e-05	9.77e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SDHD—melanoma	1.7e-05	9.74e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CSPG4—melanoma	1.7e-05	9.74e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—BSG—melanoma	1.7e-05	9.74e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—GAB2—melanoma	1.69e-05	9.67e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.68e-05	9.62e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FASN—melanoma	1.66e-05	9.46e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GPAM—melanoma	1.65e-05	9.43e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.62e-05	9.28e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	1.62e-05	9.24e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HDAC2—melanoma	1.59e-05	9.09e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FOXO4—melanoma	1.59e-05	9.09e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CXCR4—melanoma	1.59e-05	9.09e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD44—melanoma	1.57e-05	8.99e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	1.57e-05	8.98e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	1.54e-05	8.79e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	1.54e-05	8.79e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	1.54e-05	8.79e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP17A1—melanoma	1.5e-05	8.57e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.48e-05	8.46e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	1.46e-05	8.37e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—ALB—melanoma	1.46e-05	8.35e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	1.45e-05	8.3e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT3—melanoma	1.45e-05	8.29e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GNA11—melanoma	1.42e-05	8.1e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PLA2G6—melanoma	1.4e-05	8.02e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—FASN—melanoma	1.39e-05	7.92e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—SLC5A5—melanoma	1.36e-05	7.79e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	1.34e-05	7.63e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—GNAQ—melanoma	1.32e-05	7.53e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CD44—melanoma	1.32e-05	7.53e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	1.29e-05	7.38e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.29e-05	7.37e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB4—melanoma	1.28e-05	7.33e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN2B—melanoma	1.27e-05	7.26e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—CYP1B1—melanoma	1.26e-05	7.22e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—VCAN—melanoma	1.26e-05	7.2e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD86—melanoma	1.23e-05	7.02e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF1—melanoma	1.19e-05	6.81e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PDGFRA—melanoma	1.15e-05	6.6e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PRKCA—melanoma	1.14e-05	6.53e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERCC2—melanoma	1.13e-05	6.48e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAP2K2—melanoma	1.12e-05	6.38e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.11e-05	6.37e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	1.09e-05	6.23e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP17A1—melanoma	1.06e-05	6.08e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HLA-A—melanoma	1.06e-05	6.07e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—TERT—melanoma	1.06e-05	6.07e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—RAC1—melanoma	1.06e-05	6.05e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ABCB1—melanoma	1.04e-05	5.94e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HIF1A—melanoma	1.02e-05	5.81e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GNA11—melanoma	1e-05	5.74e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	9.85e-06	5.63e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—FASN—melanoma	9.83e-06	5.62e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—SLC5A5—melanoma	9.67e-06	5.52e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PRKCA—melanoma	9.57e-06	5.47e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ERCC2—melanoma	9.49e-06	5.42e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—GNAQ—melanoma	9.34e-06	5.34e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CD44—melanoma	9.34e-06	5.34e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOS2—melanoma	9.24e-06	5.28e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NOTCH1—melanoma	9.16e-06	5.23e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD80—melanoma	8.97e-06	5.12e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—CYP1B1—melanoma	8.95e-06	5.12e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—APC—melanoma	8.95e-06	5.12e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KIT—melanoma	8.95e-06	5.12e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGF—melanoma	8.85e-06	5.06e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—BRAF—melanoma	8.42e-06	4.81e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAP2K1—melanoma	7.92e-06	4.53e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CD—melanoma	7.87e-06	4.5e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.86e-06	4.49e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—FGF2—melanoma	7.54e-06	4.31e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CG—melanoma	7.5e-06	4.28e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PPARG—melanoma	7.24e-06	4.13e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MDM2—melanoma	7.05e-06	4.03e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—ERBB2—melanoma	6.95e-06	3.97e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CB—melanoma	6.86e-06	3.92e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CD4—melanoma	6.85e-06	3.91e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PRKCA—melanoma	6.79e-06	3.88e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ERCC2—melanoma	6.73e-06	3.84e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CD—melanoma	6.59e-06	3.77e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—ALB—melanoma	6.51e-06	3.72e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1B—melanoma	6.44e-06	3.68e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CTNNB1—melanoma	6.08e-06	3.47e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—CDKN1A—melanoma	5.94e-06	3.39e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PTEN—melanoma	5.93e-06	3.39e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CB—melanoma	5.75e-06	3.28e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CG—melanoma	5.31e-06	3.04e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—STAT3—melanoma	5.3e-06	3.03e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—NRAS—melanoma	5.29e-06	3.02e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PPARG—melanoma	5.13e-06	2.93e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK3—melanoma	5.07e-06	2.89e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PTEN—melanoma	4.96e-06	2.84e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MYC—melanoma	4.93e-06	2.81e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—MAPK1—melanoma	4.82e-06	2.75e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—EGFR—melanoma	4.82e-06	2.75e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CD—melanoma	4.67e-06	2.67e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—ALB—melanoma	4.61e-06	2.64e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—KRAS—melanoma	4.55e-06	2.6e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—PIK3CA—melanoma	4.18e-06	2.39e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CB—melanoma	4.07e-06	2.33e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTGS2—melanoma	4.04e-06	2.31e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—HRAS—melanoma	3.87e-06	2.21e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—IL6—melanoma	3.7e-06	2.12e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PTEN—melanoma	3.52e-06	2.01e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—PIK3CA—melanoma	3.5e-06	2e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Disease—AKT1—melanoma	3.42e-06	1.95e-05	CbGpPWpGaD
Lenalidomide—PTGS2—Metabolism—AKT1—melanoma	2.86e-06	1.63e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—PIK3CA—melanoma	2.48e-06	1.42e-05	CbGpPWpGaD
Lenalidomide—ABCB1—Metabolism—AKT1—melanoma	2.03e-06	1.16e-05	CbGpPWpGaD
